Sec Form 4 Filing - Presidio Partners 2007 GP, L.P. @ Menlo Therapeutics Inc. - 2018-03-02

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Presidio Partners 2007 GP, L.P. 2. Issuer Name and Ticker or Trading Symbol Menlo Therapeutics Inc. [ MNLO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 655 MONTGOMERY STREET, SUITE 6-161,, 3. Date of Earliest Transaction (MM/DD/YY) 03/02/2018 (Street) SAN FRANCISCO, CA94111 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/02/2018 J( 1 ) 152,062 A $ 0 152,062 I By David J. Collier ( 2 ) Common Stock 2,395,068 I By Presidio Partners 2007, L.P. ( 3 ) Common Stock 61,410 I By Presidio Partners 2007 (Parallel), L.P. ( 4 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Presidio Partners 2007 GP, L.P. 655 MONTGOMERY STREET, SUITE 6-161, SAN FRANCISCO, CA94111 X Presidio Partners 2007 (Parallel), L.P. C/O PRESIDIO PARTNERS 2007 GP, L.P. 655 MONTGOMERY STREET, SUITE 6-161 SAN FRANCISCO, CA94111 X Presidio Partners 2007, L.P. C/O PRESIDIO PARTNERS 2007 GP, L.P. 655 MONTGOMERY STREET, SUITE 6-161 SAN FRANCISCO, CA94111 X Collier David J C/O PRESIDIO PARTNERS 2007 GP, L.P. 655 MONTGOMERY STREET, SUITE 6-161 SAN FRANCISCO, CA94111 X Watson James F C/O PRESIDIO PARTNERS 2007 GP, L.P. 655 MONTGOMERY STREET, SUITE 6-161 SAN FRANCISCO, CA94111 X Sohail Faysal A. C/O PRESIDIO PARTNERS 2007 GP, L.P. 655 MONTGOMERY STREET, SUITE 6-161 SAN FRANCISCO, CA94111 X Signatures Presidio Partners 2007 GP, L.P. By: Presidio Partners 2007 GP LLC, its General Partner, /s/ David J. Collier, Manager 07/26/2018 Signature of Reporting Person Date PRESIDIO PARTNERS 2007 (Parallel), L.P. By: Presidio Partners 2007 GP, L.P, its General Partner By: Presidio Partners 2007 GP LLC, its General Partner, /s/ David J. Collier, Manager 07/26/2018 Signature of Reporting Person Date PRESIDIO PARTNERS 2007, L.P. By: Presidio Partners 2007 GP, L.P, its General Partner By: Presidio Partners 2007 GP LLC, its General Partner, /s/ David J.Collier, Manager 07/26/2018 Signature of Reporting Person Date /s/ David J. Collier 07/26/2018 Signature of Reporting Person Date /s/ James F. Watson 07/26/2018 Signature of Reporting Person Date /s/ Faysal A. Sohail 07/26/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Pro rata distribution from Velocity Pharmaceutical Development, LLC, of which the reporting person is a non-managing member. ( 2 )Securities directly held by David J. Collier, M.D., a general partner of Presidio GP (as defined below), which is the sole general partner of Presidio Partners (as defined below). ( 3 )Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein. ( 4 )Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.